Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4…
~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed,…
Black Book Research conducted this flash survey as both a service to the U.S. healthcare industry and a gesture of…
New agreement brings innovative shock wave, tPEMF therapy, monitoring, and bleeding control solutions to more than 2,200 member clinics nationwide…
First-of-its kind tool to guide HCPs on what to consider when staging patients with Mycosis Fungoides and Sézary SyndromePRINCETON, N.J.,…
90-day trial measuring change in general fatigue in chronic babesiosis patientsEnrollment expected to commence Q4 2025 and to be completed…
Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance…
MELBOURNE, Australia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company…
Call Scheduled for today, Tuesday, August 19, 2025, at 5:00 pm ETLITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos…
U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on…